Advanced search
Publication Cover
Cancer Management and Research Volume 12, 2020 - Issue
Submit an article Journal homepage
56
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Efficacy and Safety of Apatinib Treatment for Patients with Advanced Intrahepatic Cholangiocarcinoma

Guohe Lin1 Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230601, People’s Republic of China
,
Bicheng Wang2 Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-4598-7721
ORCID Icon,
Xiuwei Wu1 Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230601, People’s Republic of China
,
Tong Sun1 Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230601, People’s Republic of China
,
Lili Chen1 Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230601, People’s Republic of China
,
Canliang Lu3 Department of Hepatopancreatobiliary Surgery, Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, People’s Republic of ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-5423-2972
ORCID Icon &
Nianfei Wang1 Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230601, People’s Republic of ChinaCorrespondence[email protected]
 show all
Pages 11523-11526 | Published online: 10 Nov 2020

References

  • Wei M, Lu L, Lin P, et al. Multiple cellular origins and molecular evolution of intrahepatic cholangiocarcinoma. Cancer Lett. 2016;379(2):253–261. doi:10.1016/j.canlet.2016.02.03826940139
  • Simone V, Brunetti O, Lupo L, et al. Targeting angiogenesis in biliary tract cancers: an open option. Int J Mol Sci. 2017;18(2):418. doi:10.3390/ijms18020418
  • Weigt J, Malfertheiner P. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. Expert Rev Gastroenterol Hepatol. 2010;4(4):395–397. doi:10.1586/egh.10.4520678012
  • Pan TT, Wang W, Jia WD, et al. A single-center experience of sorafenib monotherapy in patients with advanced intrahepatic cholangiocarcinoma. Oncol Lett. 2017;13(5):2957–2964. doi:10.3892/ol.2017.584728529557
  • Lavingia V, Fakih M. Impressive response to dual BRAF and MEK inhibition in patients with BRAF mutant intrahepatic cholangiocarcinoma-2 case reports and a brief review. J Gastrointest Oncol. 2016;7(6):E98–E102. doi:10.21037/jgo.2016.09.1328078132
  • Elkrief A, Alcindor T. Molecular targets and novel therapeutic avenues in soft-tissue sarcoma. Curr Oncol. 2020;27:34–40.
  • Chen Y, Ma G, Su C, et al. Apatinib reverses alectinib resistance by targeting vascular endothelial growth factor receptor 2 and attenuating the oncogenic signaling pathway in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene-positive lung cancer cell lines. Anticancer Drugs. 2018;29(10):935–943.30074936
  • Scott L. Apatinib: a review in advanced gastric cancer and other advanced cancers. Drugs. 2018;78(7):747–758. doi:10.1007/s40265-018-0903-929663291
  • Wang LY, Gong S, Gao LP, et al. Apatinib for treating advanced intrahepatic cholangiocarcinoma after failed chemotherapy: a case report and literature review. Medicine. 2018;97(49):e13372. doi:10.1097/MD.000000000001337230544406
  • Leng J, Li DR, Huang LM, et al. Apatinib is effective as third-line and more treatment of advanced metastatic non-small-cell lung cancer: a retrospective analysis in a real-world setting. Medicine. 2019;98(36):e16967. doi:10.1097/MD.000000000001696731490378
  • Li J, Qin S, Xu J, et al. Randomized, Double-Blind, Placebo-Controlled Phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016;34(13):1448–1454. doi:10.1200/JCO.2015.63.599526884585
  • Liang L, Wen Y, Hu R, et al. Safety and efficacy of PD-1 blockade-activated multiple antigen-specific cellular therapy alone or in combination with apatinib in patients with advanced solid tumors: a pooled analysis of two prospective trials. Cancer Immunol Immunother. 2019;68(9):1467–1477. doi:10.1007/s00262-019-02375-z31451841
  • Hu X, Zhang J, Xu B, et al. Multicenter Phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer. Int J Cancer. 2014;135(8):1961–1969. doi:10.1002/ijc.2882924604288
  • Liu Z, Ou W, Li N, et al. Apatinib monotherapy for advanced non-small cell lung cancer after the failure of chemotherapy or other targeted therapy. Thorac Cancer. 2018;9(10):1285–1290. doi:10.1111/1759-7714.1283630126078
  • Yu WC, Zhang KZ, Chen SG, et al. Efficacy and safety of apatinib in patients with intermediate/advanced hepatocellular carcinoma: a prospective observation study. Medicine. 2018;97(3):e9704. doi:10.1097/MD.000000000000970429505026
  • Fang SC, Zhang HT, Zhang YM, et al. Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma. Onco Targets Ther. 2017;10:447–452. doi:10.2147/OTT.S12661328176910
  • Wu F, Zhang S, Xiong A, et al. A Phase II clinical trial of apatinib in pretreated advanced non-squamous non-small-cell lung cancer. Clin Lung Cancer. 2018;19(6):e831–e842. doi:10.1016/j.cllc.2018.06.00230026059
  • Xiao B, Wang W, Zhang D. Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials. Onco Targets Ther. 2018;11:5059–5074. doi:10.2147/OTT.S16615130174444

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.